Anti-Cisplatin modified DNA antibody [CP9/19] (ab103261)
Key features and details
- Rat monoclonal [CP9/19] to Cisplatin modified DNA
- Suitable for: ELISA
- Reacts with: Species independent
- Isotype: IgG2a
Overview
-
Product name
Anti-Cisplatin modified DNA antibody [CP9/19] -
Description
Rat monoclonal [CP9/19] to Cisplatin modified DNA -
Host species
Rat -
Tested applications
Suitable for: ELISAmore details -
Species reactivity
Reacts with: Species independent -
Immunogen
Full length protein corresponding to Cisplatin modified DNA. Cisplatin Modified Native DNA.
-
Positive control
- RNA/DNA.
-
General notes
This antibody enables the quantification of cisplatin-induced adducts on DNA. It has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
Preservative: 0.02% Sodium azide
Constituent: 99.98% PBS -
Concentration information loading...
-
Purity
Protein A/G purified -
Primary antibody notes
This antibody enables the quantification of cisplatin-induced adducts on DNA. It has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines. -
Clonality
Monoclonal -
Clone number
CP9/19 -
Myeloma
Y3/Ag1.2.3 -
Isotype
IgG2a -
Research areas
Associated products
-
Compatible Secondaries
-
Conjugation kits
-
Isotype control
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab103261 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ELISA | (1) |
Use at an assay dependent concentration.
|
Notes |
---|
ELISA
Use at an assay dependent concentration. |
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
SDS download
-
Datasheet download
References (41)
ab103261 has been referenced in 41 publications.
- Winardi D et al. Novel Aurora A Kinase Inhibitor Fangchinoline Enhances Cisplatin-DNA Adducts and Cisplatin Therapeutic Efficacy in OVCAR-3 Ovarian Cancer Cells-Derived Xenograft Model. Int J Mol Sci 23:N/A (2022). PubMed: 35163790
- Tangeda V et al. Lon upregulation contributes to cisplatin resistance by triggering NCLX-mediated mitochondrial Ca2+ release in cancer cells. Cell Death Dis 13:241 (2022). PubMed: 35296653
- Jones TM et al. Targeted CUL4A inhibition synergizes with cisplatin to yield long-term survival in models of head and neck squamous cell carcinoma through a DDB2-mediated mechanism. Cell Death Dis 13:350 (2022). PubMed: 35428778
- Nicholson HA et al. Fibroblast growth factor signalling influences homologous recombination-mediated DNA damage repair to promote drug resistance in ovarian cancer. Br J Cancer 127:1340-1351 (2022). PubMed: 35778553
- Zhang Y et al. BTF3 confers oncogenic activity in prostate cancer through transcriptional upregulation of Replication Factor C. Cell Death Dis 12:12 (2021). PubMed: 33414468